Award

ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL

  • Belfast Health & Social Care Trust

UK6: Contract award notice - Procurement Act 2023 - view information about notice types

Notice identifier: 2025/S 000-023668

Procurement identifier (OCID): ocds-h6vhtk-051a06 (view related notices)

Published 21 May 2025, 10:52am



Scope

Reference

DACPM2025-26

Description

Procurement of ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL


Contract 1. ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL,

Supplier

Contract value

  • £750,000 excluding VAT
  • £750,000 including VAT

Above the relevant threshold

Award decision date

21 May 2025

Standstill period

  • End: 2 June 2025
  • 8 working days

Earliest date the contract will be signed

16 June 2025

Contract dates (estimated)

  • 17 June 2025 to 30 June 2027
  • 2 years, 14 days

Main procurement category

Goods

CPV classifications

  • 33600000 - Pharmaceutical products

Contract locations

  • UKN - Northern Ireland

Procedure

Procedure type

Direct award


Supplier

ALLOGA UK LIMITED

  • Companies House: 03169255
  • Public Procurement Organisation Number: PBTH-6754-GVPN

Amber Park

Alfreton

DE55 2FH

United Kingdom

Region: UKF12 - East Derbyshire

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 1. ENHERTU (TRASTUZUMAB DERUXTECAN) 100MG POWDER FOR CONCENTRATE FOR SOLN FOR INFUSION VIAL,


Contracting authority

Belfast Health & Social Care Trust

  • Public Procurement Organisation Number: PLQJ-5727-JCLR

Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital

Belfast

BT12 6BA

United Kingdom

Region: UKN06 - Belfast

Organisation type: Public authority - central government

Devolved regulations that apply: Northern Ireland